DESI2 Antibody

What is DESI2 and what are its key structural characteristics?

DESI2 (desumoylating isopeptidase 2) is a cytoplasmic protein belonging to the DeSI protein family with significant roles in cellular processes. In humans, the canonical protein consists of 194 amino acid residues with a molecular mass of 21.4 kDa . Up to two different isoforms have been reported for this protein, with subcellular localization primarily in the cytoplasm . DESI2 exhibits deubiquitinating activity towards 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains, suggesting its involvement in protein degradation pathways . The protein is also known by several synonyms including CGI-146, DESI, DESI1, FAM152A, PNAS-4, PPPDE1, deubiquitinase DESI2, and C1orf121 . DESI2 gene orthologs have been identified across multiple species including mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken, indicating evolutionary conservation .

What are the most effective applications for DESI2 antibodies in research?

DESI2 antibodies have demonstrated efficacy in multiple immunodetection techniques, with Western Blot (WB) being the most widely utilized application . Many commercially available antibodies are specifically validated for WB applications, making this the gold standard for DESI2 detection . ELISA represents another common application, particularly useful for quantitative analysis of DESI2 in complex biological samples . Depending on the specific antibody, additional validated applications may include immunofluorescence (IF), immunohistochemistry (IHC), and immunoprecipitation (IP) . When selecting a DESI2 antibody, researchers should consider the specific applications they intend to use and verify that the antibody has been validated for those particular techniques. The choice between different applications depends on whether researchers need to determine protein localization (IF/IHC), protein-protein interactions (IP), or simply detect and quantify DESI2 presence (WB/ELISA).

What validation controls should be implemented when using DESI2 antibodies?

Proper validation of DESI2 antibodies requires multiple controls to ensure specificity and reliability of results. Positive controls should include cell lines or tissues known to express DESI2, while negative controls might utilize tissues from knockout models or cell lines where DESI2 expression is absent or silenced. For Western blot applications, researchers should verify that the observed band appears at the expected molecular weight of approximately 21 kDa . When using recombinant DESI2 protein as a standard, ensure its sequence matches the epitope recognized by the antibody. Pre-adsorption tests, where the antibody is incubated with purified DESI2 protein prior to the experiment, can confirm specificity by demonstrating signal reduction. Cross-reactivity testing against related proteins (especially other DeSI family members) is crucial to confirm the antibody's specificity. Finally, comparing results obtained with multiple DESI2 antibodies targeting different epitopes provides additional validation and can identify potential isoform-specific reactions.

How can DESI2 antibodies be utilized to study apoptotic pathways?

DESI2 (also known as PNAS-4) functions as a novel pro-apoptotic gene activated during the early response to DNA damage, making DESI2 antibodies valuable tools for investigating apoptotic mechanisms . When studying DESI2's role in apoptosis, researchers should employ multiple complementary techniques. Western blot analysis using DESI2 antibodies can track changes in expression levels following apoptotic stimuli or DNA damage . This should be combined with detection of established apoptotic markers such as cleaved caspase-3, PARP cleavage, and cytochrome c release. Immunofluorescence with DESI2 antibodies enables visualization of its subcellular redistribution during apoptosis, which can be coupled with TUNEL assays or Annexin V staining to correlate DESI2 localization with apoptotic events. Research has demonstrated that overexpression of DESI2 induces S phase arrest and apoptosis by activating checkpoint kinases . Therefore, co-immunoprecipitation experiments using DESI2 antibodies can identify interactions with these checkpoint proteins. Additionally, time-course experiments measuring DESI2 levels after inducing DNA damage (with UV, chemotherapeutic agents, etc.) can elucidate its temporal activation pattern and relationship to the apoptotic cascade.

What methodological approaches optimize DESI2 detection in different cellular compartments?

Detecting DESI2 across different cellular compartments requires optimization of several methodological parameters. While DESI2 is primarily localized in the cytoplasm, its distribution may change under various cellular conditions . For immunofluorescence microscopy, optimal fixation methods vary by compartment: 4% paraformaldehyde works well for cytoplasmic DESI2, while methanol fixation may better preserve nuclear structures if examining potential nuclear translocation. Permeabilization protocols should be optimized based on the cellular compartment of interest—0.1-0.5% Triton X-100 for nuclear compartments versus milder detergents like 0.1% saponin for membrane-associated structures. When performing subcellular fractionation followed by Western blotting, extraction buffers must be tailored to the compartment being isolated. Cytoplasmic fractions typically require isotonic buffers with mild detergents, while nuclear fractions need more stringent extraction conditions. Loading controls specific to each cellular compartment (e.g., GAPDH for cytoplasm, lamin for nucleus) should be used to normalize DESI2 signals. For co-localization studies, confocal microscopy with appropriate compartment markers (e.g., DAPI for nucleus, phalloidin for cytoskeleton) provides the most accurate assessment of DESI2 distribution across cellular structures.

How do DESI2 expression patterns differ between normal and cancer tissues?

DESI2 expression exhibits distinct patterns between normal and cancer tissues, making DESI2 antibodies valuable tools for comparative oncology studies. Research involving DESI2 has demonstrated significant roles in several cancer types, including colon carcinoma (CT26), lung cancer (LL2), ovarian cancer (SKOV3), and lung adenocarcinoma (A549) . When analyzing these expression differences, researchers should implement a multi-layered approach. Immunohistochemistry using DESI2 antibodies on tissue microarrays allows for high-throughput comparison across multiple cancer types and corresponding normal tissues. Quantitative analysis of staining intensity and subcellular localization should be performed using digital image analysis software to ensure objective assessment. Western blot analysis of tissue lysates provides quantitative comparison of expression levels, ideally using paired normal-tumor samples from the same patients when available. For more comprehensive evaluation, researchers should correlate DESI2 expression with clinical parameters including tumor stage, grade, and patient survival data. The pro-apoptotic function of DESI2 suggests its potential role as a tumor suppressor , therefore particular attention should be paid to decreased expression patterns in certain cancer types, which might contribute to apoptosis resistance.

How can DESI2 antibodies contribute to cancer therapy research?

DESI2 antibodies serve as essential tools in investigating the therapeutic potential of DESI2-based cancer treatments. Research has demonstrated that DESI2 gene therapy, particularly when combined with other factors like IP10, can significantly enhance antitumor activity through multiple mechanisms including apoptosis induction, angiogenesis inhibition, and immune response stimulation . When designing experiments to evaluate DESI2-based therapies, researchers should employ DESI2 antibodies to monitor expression levels in treated versus untreated tumors through immunohistochemistry and Western blotting. For mechanistic studies, DESI2 antibodies can help track cellular responses following treatment, including changes in apoptotic markers, cell cycle distribution, and activation of checkpoint kinases. In animal models, researchers have successfully used recombinant plasmids co-expressing DESI2 and IP10 encapsulated with DOTAP/Cholesterol nanoparticles to treat immunocompetent mice bearing CT26 colon carcinoma and LL2 lung cancer . This combined approach significantly inhibited tumor growth and efficiently prolonged survival of tumor-bearing mice . DESI2 antibodies are crucial for validating transgene expression in these models and correlating expression levels with therapeutic outcomes.

What considerations are important when using DESI2 antibodies for studying protein interactions?

When investigating DESI2 protein interactions using immunoprecipitation techniques, several critical considerations must be addressed for optimal results. The choice of antibody is paramount—researchers should select antibodies that recognize native conformations of DESI2 rather than denatured epitopes, as the latter may disrupt protein-protein interactions. Polyclonal antibodies often work well for immunoprecipitation due to their recognition of multiple epitopes . Cell lysis conditions must be carefully optimized to preserve protein interactions; generally, non-ionic detergents (like NP-40 or Triton X-100) at low concentrations (0.1-0.5%) maintain most interactions while dissolving membranes. Pre-clearing lysates with protein A/G beads before immunoprecipitation reduces non-specific binding. For detecting weak or transient interactions, chemical crosslinking agents (such as DSP or formaldehyde) can be employed prior to cell lysis. When analyzing DESI2's deubiquitinating activity towards 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains , researchers should include ubiquitinated substrate proteins in immunoprecipitation experiments. Reciprocal co-immunoprecipitation (pulling down with antibodies against suspected interaction partners and blotting for DESI2) provides additional validation of interactions.

What experimental approaches can elucidate DESI2's role in angiogenesis inhibition?

DESI2's involvement in angiogenesis inhibition, particularly when combined with IP10 in cancer therapy, necessitates specialized experimental approaches . When investigating this function, researchers should implement both in vitro and in vivo methodologies. For in vitro studies, endothelial cell models such as HUVECs (Human Umbilical Vein Endothelial Cells) provide an excellent system for examining anti-angiogenic effects. Cell proliferation assays using BrdU incorporation or Ki-67 staining can quantify the impact of DESI2 overexpression on endothelial cell growth. Tube formation assays on Matrigel offer a functional readout of angiogenic capacity, which can be quantified by measuring total tube length, branch points, and closed networks. For in vivo evaluation, researchers can employ Matrigel plug assays, where DESI2-expressing constructs are mixed with Matrigel and injected subcutaneously into mice, followed by histological analysis of vessel formation. In tumor models, immunohistochemical staining for CD31 (PECAM-1) on tumor sections allows quantification of microvessel density. Combined DESI2 and IP10 gene therapy has been shown to efficiently inhibit angiogenesis in tumor models, which can be mechanistically investigated through analysis of angiogenic factors (VEGF, FGF, etc.) in tumor tissue using ELISA or Western blotting with appropriate antibodies .

What are common causes of false positives/negatives when using DESI2 antibodies?

When working with DESI2 antibodies, researchers may encounter several sources of false results that require careful consideration. False positives commonly arise from antibody cross-reactivity with related proteins, particularly other members of the DeSI protein family that share sequence homology. To address this, epitope mapping and pre-adsorption tests should be performed to confirm specificity. Non-specific binding to high-abundance proteins can also generate false signals, which can be mitigated through more stringent washing steps and blocking with appropriate agents (5% BSA or milk). False negatives frequently result from epitope masking due to protein-protein interactions or post-translational modifications of DESI2. Using denaturing conditions or multiple antibodies targeting different epitopes can help overcome this limitation. Inadequate sample preparation may lead to protein degradation, particularly when working with the relatively small 21.4 kDa DESI2 protein . Including protease inhibitors and maintaining samples at 4°C throughout processing is essential. When performing immunohistochemistry, false negatives may occur due to epitope destruction during fixation; therefore, antigen retrieval methods should be optimized specifically for DESI2 detection. Additionally, since DESI2 has up to two reported isoforms , antibodies targeting isoform-specific regions may fail to detect all variants, necessitating careful antibody selection based on the research question.

How can researchers optimize antibody concentrations for different DESI2 detection methods?

Determining optimal antibody concentrations for DESI2 detection requires systematic titration across different experimental platforms. For Western blotting, researchers should perform an antibody dilution series (typically ranging from 1:500 to 1:5000) using positive control samples with known DESI2 expression . The ideal concentration provides clear detection of the expected 21 kDa band with minimal background. For immunohistochemistry and immunofluorescence, a broader range of dilutions (1:50 to 1:500) should be tested on known positive tissues, evaluating both signal intensity and specificity. For ELISA applications, a checkerboard titration approach is recommended, where both primary antibody and detection antibody concentrations are systematically varied to determine optimal signal-to-noise ratios. When developing new applications or working with challenging sample types, dot blot analysis with serial dilutions of both sample and antibody provides a rapid method for establishing preliminary working concentrations. Regardless of the application, researchers should validate that the selected concentration falls within the linear range of detection by creating a standard curve using recombinant DESI2 protein at known concentrations. Additionally, the incubation time and temperature significantly impact antibody binding kinetics; therefore, these parameters should be optimized in conjunction with concentration adjustments.

What is the most effective approach for epitope mapping of DESI2 antibodies?

Epitope mapping of DESI2 antibodies is essential for understanding their binding characteristics and potential cross-reactivity. A comprehensive epitope mapping strategy employs multiple complementary techniques. Peptide array analysis represents a high-throughput approach where overlapping synthetic peptides spanning the entire 194 amino acid sequence of DESI2 are systematically screened for antibody binding. This method precisely identifies linear epitopes but may miss conformational determinants. For conformational epitope mapping, hydrogen-deuterium exchange mass spectrometry (HDX-MS) provides valuable insights by measuring differential solvent accessibility of protein regions in the presence and absence of the antibody. X-ray crystallography of antibody-antigen complexes offers the most detailed structural information but is technically challenging and resource-intensive. A more accessible approach combines limited proteolysis with mass spectrometry, where DESI2 protein is partially digested with proteases in the presence of the antibody, which protects its binding site from digestion. Computational methods employing biophysics-informed models can complement experimental approaches by predicting antibody-antigen interactions and identifying potential epitopes . This integrated approach not only maps the epitope but also provides insights into antibody specificity, potentially allowing for computational design of antibodies with customized specificity profiles for DESI2 .

How might advanced computational models improve DESI2 antibody design and specificity?

Recent advances in computational modeling present promising opportunities for enhancing DESI2 antibody design and specificity. Biophysics-informed models, trained on experimentally selected antibodies, can associate distinct binding modes with potential ligands, enabling prediction and generation of specific variants beyond those observed in experiments . These approaches are particularly valuable when very similar epitopes need to be discriminated, as might be the case with different DESI2 isoforms or between DESI2 and closely related family members. For DESI2 antibody development, researchers could employ phage display experiments combined with high-throughput sequencing and downstream computational analysis to gain additional control over specificity profiles . The computational framework can disentangle different binding modes even when they are associated with chemically similar ligands, leading to the design of antibodies with customized specificity profiles—either with specific high affinity for a particular target epitope on DESI2 or with cross-specificity for multiple target variants . Furthermore, these models can generate novel antibody sequences not present in initial libraries but predicted to have desired specificity characteristics. The combination of biophysics-informed modeling with extensive selection experiments offers a powerful approach for designing DESI2 antibodies with precisely defined physical properties, potentially mitigating experimental artifacts and biases in traditional selection processes .

What are the emerging applications of DESI2 in combinatorial cancer therapy approaches?

DESI2's pro-apoptotic properties and its synergistic effects when combined with other factors position it as a promising candidate for novel combinatorial cancer therapy approaches. Research has demonstrated that the combination of DESI2 and IP10 gene therapy significantly enhances antitumor activity through multiple mechanisms: as an apoptosis inducer, angiogenesis inhibitor, and immune response stimulator . This multifaceted approach represents an emerging paradigm in cancer treatment that could potentially overcome resistance mechanisms associated with single-target therapies. In preclinical models, the combined gene therapy more significantly inhibited tumor growth and efficiently prolonged the survival of tumor-bearing mice compared to either gene alone . The mechanisms underlying this enhanced efficacy involve induction of apoptosis, inhibition of angiogenesis (demonstrated through inhibition of HUVEC cell proliferation in vitro), and increased infiltration of lymphocytes contributing to antitumor effects . Future research directions might explore additional combinatorial approaches, such as pairing DESI2-based therapies with immune checkpoint inhibitors, conventional chemotherapeutics, or radiation therapy. The deubiquitinating activity of DESI2 towards specific polyubiquitin chains suggests potential applications in targeting the ubiquitin-proteasome system, which is increasingly recognized as a valuable therapeutic target in cancer. Development of delivery systems that can simultaneously or sequentially deliver DESI2 with complementary therapeutic agents represents another promising avenue for investigation.

How can researchers best study the interplay between DESI2 and the immune system in cancer models?

Investigating the interplay between DESI2 and the immune system in cancer contexts requires sophisticated experimental approaches that integrate molecular, cellular, and in vivo methodologies. As demonstrated in previous research, combined DESI2 and IP10 gene therapy enhanced antitumor effects partially through increased infiltration of lymphocytes . To further elucidate these mechanisms, researchers should employ immunocompetent mouse models bearing relevant tumors, similar to previous studies with CT26 colon carcinoma and LL2 lung cancer . Flow cytometric analysis of tumor-infiltrating lymphocytes (TILs) should quantify and characterize various immune cell populations, with particular attention to CD8+ T cells, which have been shown to contribute significantly to antitumor effects in DESI2-based therapies . Depletion studies using antibodies against specific immune cell populations (e.g., anti-CD8 for CD8+ T cell depletion) can establish causal relationships between immune components and therapeutic outcomes. Multiplex immunohistochemistry or imaging mass cytometry of tumor sections allows visualization of spatial relationships between DESI2-expressing cells and immune infiltrates. For mechanistic insights, ex vivo co-culture systems combining DESI2-expressing cancer cells with various immune cell populations can elucidate direct interactions. Analysis of cytokine/chemokine profiles in the tumor microenvironment following DESI2 therapy may reveal important mediators of immune activation. Additionally, evaluation of tumor antigen presentation and T cell receptor repertoire diversity could provide insights into whether DESI2-induced apoptosis enhances immunogenic cell death and subsequent adaptive immune responses.